COMMUNIQUÉS West-GlobeNewswire

DigitalOptometrics® Announces Next Evolution in Tele-Ophthalmic Care at Vision Expo East
12/03/2026
Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- New partnership with Eyoto reinforces DigitalOptometrics’ leadership in delivering consistent, high-quality remote eye exams inside the clinic. Vision Expo East — [...]
Koelis Announces Innovative Products at EAU 2026 enhancing MRI Fusion Biopsy Workflows and promoting Focal Therapy in Prostate Cancer
12/03/2026
GRENOBLE, France, March 12, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, announced today [...]
Aclarion CEO Brent Ness to Attend LSI USA 2026
12/03/2026
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary [...]
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12/03/2026
Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted [...]
Chinese medical team enables 30 type 1 diabetes patients to discontinue insulin through integrative medicine
12/03/2026
SHENZHEN, China, March 12, 2026 (GLOBE NEWSWIRE) -- On March 10, 2026, the team led by Dr. An Chiying at Shenzhen Hengsheng Hospital, affiliated with Shanghai Fosun Health, publicly announced that through an innovative [...]
SK pharmteco Announces CGMP Qualification of its Commercial-Scale Viral Vector Manufacturing Facility in France
12/03/2026
RANCHO CORDOVA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- SK pharmteco today announced the successful CGMP qualification of its manufacturing facility in Corbeil-Essonnes, France. This state-of-the-art plant is now [...]
Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia
12/03/2026
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon , a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet [...]
Cbio A/S Receives European Regulatory Clearance to Begin First-in-Human Clinical Trial of Next-Generation T-Cell Therapy in late-stage Cervical Cancer
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 (GLOBE NEWSWIRE) -- Cbio A/S today announced that it has received regulatory clearance to begin a first-in-human Phase I/IIa clinical trial of novoleucel, the company’s next- [...]
Allegro’s osteoarthritis hydrogel resolves lameness in animal study
12/03/2026
The hydrogel resolved lameness in 72% of horses treated Horses provide a strong translational model for human osteoarthritis Clinical investigation authorized by Belgian regulatory authority Allegro’s hydrogel is first- [...]
Novo Holdings announces 2025 Annual Results
12/03/2026
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 billion or €2.0 [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the second tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million [...]
Bavarian Nordic Publishes Annual Report 2025
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) today published its annual report for 2025. The consolidated, audited results were in line with the preliminary results announced on February 12, [...]
Ipsen appoints Michelle C. Werner as EVP, President of North America
12/03/2026
PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle [...]
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 12, 2026 (GLOBE NEWSWIRE) -- Under the BioVersys and GSK collaboration agreement, AlpE clinical development advances with first patient dosed in Phase [...]
Full Year 2025 Trading Update
12/03/2026
Ad hoc announcement pursuant to Art. 53 LR AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth Pratteln, Switzerland, March 12, 2026 – Santhera Pharmaceuticals (SIX: SANN) today provides [...]
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
12/03/2026
Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 [...]
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
12/03/2026
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD [...]
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
11/03/2026
Nyxoah to Participate in the Oppenheimer 36 th Annual Healthcare MedTech & Services Conference Mont-Saint-Guibert, Belgium – March 11, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services
11/03/2026
Nyxoah Participera à la 36ème Conférence Annuelle Oppenheimer Healthcare MedTech & Services Mont-Saint-Guibert, Belgique – 11 mars 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » [...]

Pages